Fiera Capital Corp Buys 249,674 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR

Fiera Capital Corp boosted its stake in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 31.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,044,831 shares of the company’s stock after purchasing an additional 249,674 shares during the period. Fiera Capital Corp’s holdings in Immunocore were worth $36,266,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Leonteq Securities AG bought a new stake in Immunocore during the 4th quarter valued at about $30,000. Harbour Investments Inc. lifted its holdings in Immunocore by 60.2% during the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after buying an additional 388 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Immunocore by 37.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock valued at $74,000 after buying an additional 572 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in Immunocore by 117.4% during the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock valued at $97,000 after buying an additional 1,700 shares in the last quarter. Finally, State of Tennessee Department of Treasury purchased a new stake in Immunocore in the second quarter worth about $132,000. Institutional investors own 84.50% of the company’s stock.

Immunocore Stock Down 1.8%

Shares of IMCR stock opened at $27.79 on Tuesday. Immunocore Holdings PLC Sponsored ADR has a 1-year low of $27.56 and a 1-year high of $40.71. The stock’s fifty day moving average price is $29.72 and its 200 day moving average price is $32.58. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.18 and a quick ratio of 4.15. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -50.53 and a beta of 0.74.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.51. The company had revenue of $106.68 million during the quarter, compared to analysts’ expectations of $145.20 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The firm’s revenue was up 13.6% compared to the same quarter last year. During the same period last year, the business posted $0.10 earnings per share. On average, research analysts expect that Immunocore Holdings PLC Sponsored ADR will post 0.06 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on IMCR. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research note on Monday, April 20th. Wall Street Zen raised shares of Immunocore from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Mizuho set a $38.00 price target on shares of Immunocore in a research report on Thursday, February 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a research report on Tuesday, April 21st. Finally, Zacks Research raised shares of Immunocore from a “strong sell” rating to a “strong-buy” rating in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Immunocore has a consensus rating of “Moderate Buy” and an average price target of $56.71.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.